• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    2/14/23 5:11:29 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    SC 13G/A 1 tm236584d12_sc13ga.htm SC 13G/A

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    AXSOME THERAPEUTICS, INC.

    (Name of Issuer)

     

    COMMON STOCK

    (Title of Class of Securities)

     

    05464T104

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    Venrock Healthcare Capital Partners II, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    PN
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    2

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    VHCP Co-Investment Holdings II, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    OO
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    3

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    Venrock Healthcare Capital Partners III, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    PN
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    4

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    VHCP Co-Investment Holdings III, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    OO
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    5

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    VHCP Management II, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    OO
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    6

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    VHCP Management III, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    OO
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    7

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    Shah, Nimish
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    IN
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    8

     

     

    CUSIP No. 05464T104
     
      1. Name of Reporting Persons
    Koh, Bong
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    IN
               
                 

     

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-III”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons).”

     

    9

     

     

    CUSIP No. 05464T104

     

    Introductory Note: This Schedule 13G/A is filed on behalf of (i) Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP-III”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP-III Co-Invest”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-III”), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-II, VCHCP-II Co-Invest, VHCP-III, VCHCP-III Co-Invest, VHCPM-II, VHCPM-III and Shah, the “Reporting Persons”) in respect of Common Stock of Axsome Therapeutics, Inc.

     

    Item 1.
     
      (a) Name of Issuer
    Axsome Therapeutics, Inc.
      (b)

    Address of Issuer’s Principal Executive Offices

    200 Broadway, 3rd Floor

    New York, NY 10038

     
    Item 2.
     
      (a)

    Name of Person Filing
    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    VHCP Management II, LLC

    VHCP Management III, LLC

    Nimish Shah

    Bong Koh

      (b) Address of Principal Business Office or, if none, Residence
             
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    
      (c)

    Citizenship

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

      (d)

    Title of Class of Securities

    Common Stock

      (e)

    CUSIP Number

    05464T104

     

    10

     

     

    CUSIP No. 05464T104
    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
       
    Item 4. Ownership
       
      (a) Amount beneficially owned as of December 31, 2022:
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
         
      (b) Percent of class as of December 31, 2022:
          Venrock Healthcare Capital Partners II, L.P.   0.0 %  
          VHCP Co-Investment Holdings II, LLC   0.0 %  
          Venrock Healthcare Capital Partners III, L.P.   0.0 %  
          VHCP Co-Investment Holdings III, LLC   0.0 %  
          VHCP Management II, LLC   0.0 %  
          VHCP Management III, LLC   0.0 %  
          Nimish Shah   0.0 %  
          Bong Koh   0.0 %  
         
      (c) Number of shares as to which the person has, as of December 31, 2022:
        (i) Sole power to vote or to direct the vote
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
                     

     

    11

     

     

           
        (ii) Shared power to vote or to direct the vote
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
           
        (iii) Sole power to dispose or to direct the disposition of
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
           
        (iv) Shared power to dispose or to direct the disposition of
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
           
                     

     

    Item 5. Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  x

     

    12

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
     
    Not Applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
       
    Not Applicable
     
    Item 8. Identification and Classification of Members of the Group
       
    Not Applicable
     
    Item 9. Notice of Dissolution of a Group
       
    Not Applicable
     
    Item 10. Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    13

     

     

    CUSIP No. 05464T104

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    Nimish Shah   Bong Koh
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      David L. Stepp, as attorney-in-fact     David L. Stepp, as attorney-in-fact
             
    Venrock Opportunities Fund, L.P.   Venrock Opportunities Management, LLC
             
    By: Venrock Opportunities Management, LLC   By: /s/ David L. Stepp
    Its: General Partner     Name: David L. Stepp
            Its: Authorized Signatory
    By: /s/ David L. Stepp      
      Name: David L. Stepp        
      Its: Authorized Signatory        

     

    14

     

     

    CUSIP No. 05464T104

     

    EXHIBITS

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed January 28, 2019)

    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed January 28, 2019)

    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed January 28, 2019)

     

    15

      

    Get the next $AXSM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    More analyst ratings

    $AXSM
    SEC Filings

    See more
    • SEC Form 144 filed by Axsome Therapeutics Inc.

      144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

      6/17/25 4:01:01 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      6/10/25 7:24:12 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      6/9/25 4:30:53 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

      NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat

      7/9/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

      NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders will discuss the company's current indications in neurology and psychiatry. Members of the Axsome management team will provide an overview of the clinical development programs. The presenters will be available to answer questions at the e

      7/7/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

      NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month. "Alzheimer's & Brain Awareness Month offers the perfect opportunity for all Americans to take charge of their brain health," said Sarah Fried, Vice President of Corporate Initiatives at the Alzheimer's Association. "For the first time ever there are now more than 7

      6/20/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Murdock Hunter R. exercised 13,514 shares at a strike of $29.91 and sold $1,370,647 worth of shares (13,514 units at $101.42) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/23/25 7:42:47 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Murdock Hunter R. exercised 22,500 shares at a strike of $29.91 and sold $2,276,850 worth of shares (22,500 units at $101.19) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/18/25 9:16:04 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Coleman Mark

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      6/10/25 7:00:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Axsome Therapeutics with a new price target

      Morgan Stanley resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $190.00

      7/3/25 7:49:15 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Axsome Therapeutics with a new price target

      Oppenheimer initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $185.00

      6/3/25 7:47:30 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Axsome Therapeutics with a new price target

      Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

      4/7/25 8:43:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

      Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      8/19/22 12:36:14 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      11/28/23 6:51:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

      NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

      10/11/23 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 3:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 7:26:39 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/13/24 4:58:57 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Financials

    Live finance-specific insights

    See more
    • Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

      NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat

      7/9/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care